David Hering, Invivyd CEO
March 25, 2024 10:50 AM EDTUpdated March 26, 01:10 PM
R&D

In­vivyd scores EUA for Covid-19 pre­ven­tion drug Pem­gar­da

Katherine Lewin

News Reporter

The FDA gave the green light to In­vivyd’s Pem­gar­da for Covid-19 pre­ven­tion in high-risk im­muno­com­pro­mised pa­tients, is­su­ing an emer­gency use au­tho­riza­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times